Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes

Kexin Li; Xun Sun; Hudie Li; Hailan Ma; Meng Zhou; Kazumasa Minami; Keisuke Tamari; Kazuhiko Ogawa; Pankita H. Pandya; M. Reza Saadatzadeh; Melissa A. Kacena; Karen E. Pollok; Bai-Yan Li; Hiroki Yokota

doi:10.1016/j.gendis.2022.08.007

您当前的位置：

首页 >

文章列表页 >

Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes

Full-length article | 更新时间：2023-08-29

- Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes
- Genes & Diseases Vol. 10, Issue 4, (2023)
- 作者机构：
  
  1. Department of Pediatrics, Indiana University School of Medicine,IN,Indianapolis,USA,46202
  2. Indiana Center for Musculoskeletal Health, Indiana University School of Medicine,IN,Indianapolis,USA,46202
  3. Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita,Osaka,Japan,565-0871
  4. Department of Pharmacology, School of Pharmacy, Harbin Medical University,Heilongjiang,Harbin,China,150081
  5. Simon Comprehensive Cancer Center, Indiana University School of Medicine,IN,Indianapolis,USA,46202
  6. Department of Orthopaedic Surgery, Indiana University School of Medicine,IN,Indianapolis,USA,46202
  7. Department of Biomedical Engineering, Indiana University Purdue University Indianapolis,IN,Indianapolis,USA,46202
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.08.007
  CLC：
- Published：2023，
  
  Published Online：1 July 2023，
扫描看全文
Kexin Li, Xun Sun, Hudie Li, et al. Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes. [J]. Genes & Diseases 10(4).(2023)
DOI：

Kexin Li, Xun Sun, Hudie Li, et al. Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes. [J]. Genes & Diseases 10(4).(2023) DOI： 10.1016/j.gendis.2022.08.007.

摘要

Abstract

Cancer cells tend to develop resistance to chemotherapy and enhance aggressiveness. A counterintuitive approach is to tame aggressiveness by an agent that acts opposite to chemotherapeutic agents. Based on this strategy

induced tumor-suppressing cells (iTSCs) have been generated from tumor cells and mesenchymal stem cells. Here

we examined the possibility of generating iTSCs from lymphocytes by activating PKA signaling for suppressing the progression of osteosarcoma (OS). While lymphocyte-derived CM did not present anti-tumor capabilities

the activation of PKA converted them into iTSCs. Inhibiting PKA conversely generated tumor-promotive secretomes. In a mouse model

PKA-activated CM suppressed tumor-induced bone destruction. Proteomics analysis revealed that moesin (MSN) and calreticulin (Calr)

which are highly expressed intracellular proteins in many cancers

were enriched in PKA-activated CM

and they acted as extracellular tumor suppressors through CD44

CD47

and CD91. The study presented a unique option for cancer treatment by generating iTSCs that secret tumor-suppressive proteins such as MSN and Calr. We envision that identifying these tumor suppressors and predicting their binding partners such as CD44

which is an FDA-approved oncogenic target to be inhibited

may contribute to developing targeted protein therapy.

关键词

Keywords

CalreticulinLymphocytesMoesinOsteosarcomaPKAProteome

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The generation and use of animal models of osteosarcoma in cancer research

Integrative transcriptome analysis identifies MYBL2 as a poor prognosis marker for osteosarcoma and a pan-cancer marker of immune infiltration

Aberrant LETM1 elevation dysregulates mitochondrial functions and energy metabolism and promotes lung metastasis in osteosarcoma

Cellular senescence-driven transcriptional reprogramming of the MAFB/NOTCH3 axis activates the PI3K/AKT pathway and promotes osteosarcoma progression

Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway

Related Author

Zhicai Zhang

Jianxiang Liu

Xin Huang

Yizhong Peng

Fengxia Chen

Deyao Shi

Haoyu Guo

Feifei Pu

Related Institution

Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University

Department of Orthopedics, Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital), Tongji Medical College, Huazhong University of Science and Technology

Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital

⁰